395 related articles for article (PubMed ID: 31096036)
1. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I
Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
[TBL] [Abstract][Full Text] [Related]
3. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
[TBL] [Abstract][Full Text] [Related]
5. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
Kalberg C; O'Dell D; Galkin D; Newlands A; Fahy WA
Drugs R D; 2016 Jun; 16(2):217-27. PubMed ID: 27028749
[TBL] [Abstract][Full Text] [Related]
6. Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.
Maleki-Yazdi MR; Singh D; Anzueto A; Tombs L; Fahy WA; Naya I
Adv Ther; 2017 Jan; 33(12):2188-2199. PubMed ID: 27796912
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
[TBL] [Abstract][Full Text] [Related]
8. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
[TBL] [Abstract][Full Text] [Related]
10. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
[TBL] [Abstract][Full Text] [Related]
11. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.
Lipson DA; Birk R; Brealey N; Zhu CQ
Adv Ther; 2020 Dec; 37(12):4894-4909. PubMed ID: 33011864
[TBL] [Abstract][Full Text] [Related]
12. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.
Siler TM; Kerwin E; Singletary K; Brooks J; Church A
COPD; 2016; 13(1):1-10. PubMed ID: 26451734
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
Rodrigo GJ; Neffen H
Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635
[TBL] [Abstract][Full Text] [Related]
18. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
Siler TM; Donald AC; O'Dell D; Church A; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2016; 11():971-9. PubMed ID: 27274218
[TBL] [Abstract][Full Text] [Related]
19. Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities.
Kalhan R; Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; MacKnight SD; Hahn B
Int J Chron Obstruct Pulmon Dis; 2021; 16():1149-1161. PubMed ID: 33911860
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients.
Miravitlles M; Gáldiz JB; Huerta A; Villacampa A; Carcedo D; Garcia-Rio F
Int J Chron Obstruct Pulmon Dis; 2016; 11():123-32. PubMed ID: 26848262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
